{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:42:26Z","timestamp":1786653746950,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>We present a case of polyarticular synovitis following alendronate treatment for osteoporosis.<\/jats:p>\n                    <jats:p>The patient had no evidence of rheumatoid arthritis, pyrophosphate arthropathy, or seronegative\/seropositive arthritis. Our main aim in this study is to highlight the potential adverse effects of alendronate and to warn orthopedic surgeons about the possibility of such a side effect that might lead orthopedic surgeons to administer wrong and unnecessary treatments like arthrocentesis. The withdrawal of alendronate is found to be the treatment of choice. Alendronate should be considered as a possible cause of synovitis or polyarthritis in patients treated with this agent in the absence of any other pathology. An association between alendronate and synovitis has rarely been described in the literature. We present a patient who developed polyarticular synovitis after treatment with alendronate and responded to its withdrawal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0022-3859.174160","type":"journal-article","created":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T08:14:02Z","timestamp":1452845642000},"page":"126-128","source":"Crossref","is-referenced-by-count":4,"title":["Possible alendronate-induced polyarticular synovitis"],"prefix":"10.4103","volume":"62","author":[{"given":"K","family":"G\u00f6kkus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Yazicioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Sagtas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Uyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AT","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-14-20240205","first-page":"144","article-title":"Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention","volume":"7","author":"Bock","year":"2007","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"R3-14-20240205","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"R4-14-20240205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","article-title":"Comparative tolerability of drug therapies for hypercalcaemia of malignancy","volume":"21","author":"Zojer","year":"1999","journal-title":"Drug Saf"},{"key":"R5-14-20240205","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1634\/theoncologist.9-90004-28","article-title":"Safety of intravenous and oral bisphosphonates and compliance with dosing regimens","volume":"9","author":"Conte","year":"2004","journal-title":"Oncologist"},{"key":"R8-14-20240205","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0928-0987(98)00065-7","article-title":"Contrasting effects of alendronate and clodronate on RAW 264 macrophages: The role of a bisphosphonate metabolite","volume":"8","author":"Makkonen","year":"1999","journal-title":"Eur J Pharm Sci"},{"key":"R9-14-20240205","first-page":"829","article-title":"Acute polyarthritis related to once-weekly alendronate in a woman with osteoporosis","volume":"31","author":"Gerster","year":"2004","journal-title":"J Rheumatol"},{"key":"R10-14-20240205","first-page":"6","article-title":"Alendronate and risedronate for the treatment of postmenopausal osteoporosis: Clinical profiles of the once-weekly and once-daily dosing formulations","volume":"6","author":"Emkey","year":"2004","journal-title":"Med Gen Med"},{"key":"R11-14-20240205","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2005.12.019","article-title":"Improving compliance and persistence with bisphosphonate therapy for osteoporosis","volume":"119","author":"Emkey","year":"2006","journal-title":"Am J Med"},{"key":"R12-14-20240205","first-page":"20","article-title":"Alendronate and risedronate: What you need to know about their upper gastrointestinal tract toxicity","volume":"2","author":"Baker","year":"2002","journal-title":"Rev Gastroenterol Disord"},{"key":"R13-14-20240205","first-page":"537","article-title":"Alendronate-induced synovitis","volume":"35","author":"Gwynne Jones","year":"2008","journal-title":"J Rheumatol"},{"key":"R14-14-20240205","first-page":"1583","article-title":"Persistent polyarticular synovitis after treatment with alendronate","volume":"169","author":"Frederiksen","year":"2007","journal-title":"Ugeskr Laeger"},{"key":"R15-14-20240205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/bmj.330.7482.74","article-title":"Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome","volume":"330","author":"Jones","year":"2005","journal-title":"BMJ"},{"key":"R16-14-20240205","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005257-201662020-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:51Z","timestamp":1786650111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005257-201662020-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0022-3859.174160","relation":{},"ISSN":["0022-3859"],"issn-type":[{"value":"0022-3859","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}